Biogen Exec Says LEQEMBI Is Going To Do Very Well Whether A Competitor Will Come Or Not; On Lilly's Experimental Alzheimer's Drug, Says "It Will Help To Grow The Market"
Portfolio Pulse from Benzinga Newsdesk
Biogen's executive expressed confidence in the success of their Alzheimer's drug, LEQEMBI, regardless of competition. The executive also mentioned that Eli Lilly's experimental Alzheimer's drug will help grow the market. This was stated at the Goldman Sachs Conference.
June 12, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biogen's executive expressed confidence in the success of their Alzheimer's drug, LEQEMBI, regardless of competition.
The executive's confidence in LEQEMBI's success, regardless of competition, is likely to positively impact Biogen's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Biogen's executive mentioned that Eli Lilly's experimental Alzheimer's drug will help grow the market.
The mention of Eli Lilly's experimental Alzheimer's drug contributing to market growth is likely to have a positive impact on Eli Lilly's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80